-

10:22:27 PM

RHHBY Stock News

RHHBY - Roche Holding AG

11/16/22 1:00 AM

OTC : RHHBY

Roche receives U.S. FDA Emergency Use Authorization for its high-throughput test to detect monkeypox virus

In May 2022, Roche was one of the first companies to develop a suite of tests to detect the monkeypox virus and aid in the understanding of why and how the disease is spreading. cobas MPXV for use on cobas 6800/8800 Systems is the first monkeypox virus test granted EUA following evaluation in

RHEA-AI

neutral

11/15/22 6:00 AM

OTC : RHHBY

Jnana Therapeutics Announces Second Collaboration with Roche to Address Challenging-to-Drug Targets in Cancer, Immune-Mediated and Neurological Diseases

Jnana to leverage its RAPID chemoproteomics platform to discover novel small molecule drugs directed to targets across a diverse range of target classes in cancer, immune-mediated and neurological diseases.Jnana will receive $50 million upfront, significant near-term milestone payments, and is

RHEA-AI

very positive

11/14/22 1:05 AM

OTC : RHHBY

Genentech Provides Update on Phase III GRADUATE Program Evaluating Gantenerumab in Early Alzheimer’s Disease

Genentech, a member of the Roche Group, today announced results from the Phase III GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment due to Alzheimer’ s and mild Alzheimer’ s dementia, collectively called early Alzheimer’ s disease. The studies did not meet their primary endpoints of slowing clinical decline.

RHEA-AI

negative

11/14/22 1:00 AM

OTC : RHHBY

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease

Phase III GRADUATE studies did not meet their primary endpoints of slowing clinical decline in people with early Alzheimer’s The level of beta-amyloid removal by gantenerumab was lower than expected Topline data will be presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference Roche

RHEA-AI

negative

11/10/22 8:05 AM

OTC : RHHBY

covid-19

Roche launches Pilot brand, expands retail channels for COVID-19 At-Home Test

The COVID-19 At-Home Test that tens of millions of Americans received via the U.S. government is now available over-the-counter nationwide under the new Pilot name and brand. Accurate, fast and easy to use, the Pilot COVID-19 At-Home Test is the first over-the-counter test launched by Roche

RHEA-AI

neutral

11/09/22 1:00 AM

OTC : RHHBY

STRONG-HF study results demonstrate clear benefits for acute heart failure patients

STRONG-HF study primary outcomes showed significant reduction of all cause death or acute heart failure readmissions, at day 180, when the study strategy was implemented Rapid, simultaneous up-titration of therapies, and close follow-up, led to increased patient quality of life. The Roche Elecsys ®

RHEA-AI

neutral

11/04/22 2:00 AM

OTC : RHHBY

Roche introduces the navify brand for its digital health solutions at HLTH 2022

Roche unifies its digital health portfolio under the navify brand, providing a range of next generation software solutions. The navify portfolio uses digital solutions, analytics and data science to provide insights that address today's real-world challenges in health, enabling confident decisions

RHEA-AI

positive

11/03/22 9:00 AM

OTC : RHHBY, CHGCY

conferences

Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs

Genentech, a member of the Roche Group, today announced that it will present new data from its industry-leading hematology portfolio at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022. “We continually strive to improve patient outcomes by exploring new treatment options across blood disorders, such as lymphomas and rare...

RHEA-AI

neutral

11/03/22 9:00 AM

OTC : RHHBY

conferences

Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs

Interim data from phase III HAVEN 7 study reinforce Hemlibra’s efficacy and safety in infants with severe haemophilia A without factor VIII inhibitors 1 New and updated data support use of Polivy in diffuse large B-cell lymphoma, including its potential as a treatment option for previously

RHEA-AI

neutral

11/01/22 8:00 AM

OTC : RHHBY

Roche introduces the cobas 5800, a new molecular diagnostic system to expand access to PCR testing in the U.S.

cobas 5800 is a new compact addition to the Roche molecular diagnostics portfolio that provides a scalable, high performance testing solution for labs of all sizes. Infectious diseases, such as HIV, Hepatitis, transplant associated viral illnesses, and respiratory and STIs, represent an

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next